Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Karen A. Dawes currently holds 91,821 shares of PDL BIOPHARMA, INC. (PDLI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Karen A. Dawes has been a net seller of PDLI stock. They have purchased $128.6K and sold $19.0M worth of shares.
Karen A. Dawes's most recent insider trade was on Dec 17, 2025, when they sold 275 shares at $161.00 per share.
Karen A. Dawes serves as Executive at PDL BIOPHARMA, INC. (PDLI). They have executed 149 insider transactions totaling $19.1M over their tenure at the company.
Karen A. Dawes holds the position of Executive at PDL BIOPHARMA, INC., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Karen A. Dawes has shown a selling trading pattern, with $128.6K in total purchases and $19.0M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Karen A. Dawes was on May 25, 2022, when they sold $1.2M worth of RGEN shares. This transaction involved 7,677 shares at $150.19 per share.
Karen A. Dawes currently owns 91,821 shares of PDL BIOPHARMA, INC. (PDLI), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Karen A. Dawes's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Karen A. Dawes has 149 Form 4 filings on record as an insider at PDL BIOPHARMA, INC..
Set alerts for Karen A. Dawes and 40,000+ other insiders.